Related Experiment Video
Updated: Aug 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients
1Division of Cardiology, Department of Medicine, University of California, San Francisco 94143, USA. kkhush@medicine.ucsf.edu
Abstract:
The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management

